Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors

References

• Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 370(9584), 342–350 (2007).
   PubMed Web of Science ®Google Scholar
• Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract. Res. Clin. Haematol. 22(3), 295–302 (2009).
   PubMed Web of Science ®Google Scholar
• Rohrbacher M, Berger U, Hochhaus A et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23(3), 602–604 (2009).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl J. Med. 355(23), 2408–2417 (2006).
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl J. Med. 362(24), 2251–2259 (2010).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl J. Med. 362(24), 2260–2270 (2010).
   PubMed Web of Science ®Google Scholar
• Valent P. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Haematologica 96(10), 1395–1397 (2011).
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Gugliotta G, Palandri F, Martinelli G, Baccarani M. Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. Leuk. Lymphoma 51(4), 583–591 (2010).
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2), 129–141 (2005).
   PubMed Web of Science ®Google Scholar
• Breccia M, Finsinger P, Loglisci G et al. Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population. Ann Hematol. 91(9), 1345–1349 (2012).
   PubMed Web of Science ®Google Scholar
• Soverini S, Hochhaus A, Nicolini FE et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5), 1208–1215 (2011).
   PubMed Web of Science ®Google Scholar
• Costa C, Sgobio C, Siliquini S et al. Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain 135(Pt 6), 1884–1899 (2012).
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin. Oncol. 26(19), 3204–3212 (2008).
   PubMed Web of Science ®Google Scholar
• Vidiri A, Pace A, Fabi A et al. Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation. J. Exp. Clin. Can. Res. 31, 33 (2012).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Frustaci AM, Gentile G et al. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica 97(4), 560–567 (2012).
   PubMed Web of Science ®Google Scholar
• Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117(8), e75–87 (2011).
   PubMed Web of Science ®Google Scholar
• Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann. Fam. Med. 7(4), 357–363 (2009).
   PubMed Web of Science ®Google Scholar
• Starfield B. Threads and yarns: weaving the tapestry of comorbidity. Ann. Fam. Med. 4(2), 101–103 (2006).
   PubMed Web of Science ®Google Scholar
• Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch. Intern. Med. 162(20), 2269–2276 (2002).
   PubMed Web of Science ®Google Scholar
• Boyd CM, Vollenweider D, Puhan MA. Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases. PLoS ONE 7(8), e41601 (2012).
   Web of Science ®Google Scholar
• Fortin M, Soubhi H, Hudon C, Bayliss EA, Van Den Akker M. Multimorbidity's many challenges. BMJ 334(7602), 1016–1017 (2007).
   Google Scholar
• Ritchie C. Health care quality and multimorbidity: the jury is still out. Med. Care 45(6), 477–479 (2007).
   PubMed Web of Science ®Google Scholar
• Van Den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J. Clin. Epidemiol. 51(5), 367–375 (1998).
   PubMed Web of Science ®Google Scholar
• Rhee SH, Hewitt JK, Lessem JM, Stallings MC, Corley RP, Neale MC. The validity of the Neale and Kendler model-fitting approach in examining the etiology of comorbidity. Behav. Gene. 34(3), 251–265 (2004).
   PubMed Web of Science ®Google Scholar
• Starfield B, Weiner J, Mumford L, Steinwachs D. Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv. Res. 26(1), 53–74 (1991).
   PubMed Web of Science ®Google Scholar
• Karlamangla A, Tinetti M, Guralnik J, Studenski S, Wetle T, Reuben D. Comorbidity in older adults: nosology of impairment, diseases, and conditions. J. Gerontol. A. Biol. Sci. Med. Sci. 62(3), 296–300 (2007).
   PubMed Web of Science ®Google Scholar
• Valderas JM, Alonso J. Patient reported outcome measures: a model-based classification system for research and clinical practice. QualLife Res. 17(9), 1125–1135 (2008).
   Google Scholar
• Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J. Gerontol. A. Biol. Sci. Med. Sci. 59(3), 255–263 (2004).
   PubMed Web of Science ®Google Scholar
• Espallargues M, Philp I, Seymour DG et al. Measuring case-mix and outcome for older people in acute hospital care across Europe: the development and potential of the ACMEplus instrument. QJM 101(2), 99–109 (2008).
   PubMed Web of Science ®Google Scholar
• Nardi R, Scanelli G, Corrao S, Iori I, Mathieu G, Cataldi Amatrian R. Co-morbidity does not reflect complexity in internal medicine patients. Eur. J. Intern. Med. 18(5), 359–368 (2007).
   PubMed Web of Science ®Google Scholar
• Safford MM, Allison JJ, Kiefe CI. Patient complexity: more than comorbidity. the vector model of complexity. J. Gen. Inter. Med. 22(Suppl. 3), 382–390 (2007).
   PubMed Web of Science ®Google Scholar
• Jadad AR, To MJ, Emara M, Jones J. Consideration of multiple chronic diseases in randomized controlled trials. JAMA 306(24), 2670–2672 (2011).
   PubMed Web of Science ®Google Scholar
• Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297(11), 1233–1240 (2007).
   PubMed Web of Science ®Google Scholar
• Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA 298(10), 1209–1212 (2007).
   PubMed Web of Science ®Google Scholar
• Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294(6), 716–724 (2005).
   PubMed Web of Science ®Google Scholar
• Rousselot P, Cony-Makhoul P, Nicolini F et al. Long-term safety and efficacy of imatinib mesylate (Gleevec(R)) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study. Am. J. Hematol 88(1), 1–4 (2013).
   PubMed Web of Science ®Google Scholar
• Gugliotta G, Castagnetti F, Palandri F et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 117(21), 5591–5599 (2011).
   PubMed Web of Science ®Google Scholar
• Fogliatto L, Capra M, Schaan M et al. Impact of Comorbidity In Event-Free Survival, Toxicity and Adherence to Treatment In Chronic Myeloid Leukemia Patients Treated with Imatinib. ASH Annual Meeting Abstracts 116(21), 2296 (2010).
   Google Scholar
• Breccia M, Luciano L, Latagliata R et al. Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. ASH Annual Meeting Abstracts 118(21), 2751 (2011).
   Google Scholar
• Breccia M, Latagliata R, Stagno F et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica 96(10), 1457–1461 (2011).
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Cortes JE, Kantarjian H et al. Safety and efficacy of dasatinib (DAS) versus imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia In Chronic Phase (CML-CP): analysis of the DASISION trial. ASH Annual Meeting Abstracts 116(21), 3421 (2010).
   Google Scholar
• Saglio G, Hochhaus A, Cortes JE et al. Safety and efficacy of dasatinib versus imatinib by baseline cardiovascular comorbidity in patients with chronic myeloid leukemia in Chronic Phase (CML-CP): analysis of the DASISION trial. ASH Annual Meeting Abstracts 116(21), 2286 (2010).
   Google Scholar
• Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3), 409–429 (2009).
   PubMed Web of Science ®Google Scholar
• Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25(2), 201–210 (2011).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Baccarani M, Guilhot F et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. 28(3), 424–430 (2010).
   Google Scholar
• Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110(4), 1233–1237 (2007).
   PubMed Web of Science ®Google Scholar
• Hatfield A, Owen S, Pilot PR. In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat. Med. 13(1), 13; author reply 15–16 (2007).
   PubMed Web of Science ®Google Scholar
• Yu H, Xie YH, Fan HH, Zheng B, Xie Y. Clinical and laboratory studies of expression of cyclin A in leukemia cells. Zhongguo shi yan xue ye xue za zhi 11(2), 146–152 (2003).
   PubMedGoogle Scholar
• Townsley CA, Chan KK, Pond GR, Marquez C, Siu LL, Straus SE. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer 6, 34 (2006).
   PubMed Web of Science ®Google Scholar
• Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 116(2), 377–386 (2010).
   PubMed Web of Science ®Google Scholar
• De Lavallade H, Punnialingam S, Milojkovic D et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br. J. Haematol. 141(5), 745–747 (2008).
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, O'brien S et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J. Clin. Oncol. 25(25), 3908–3914 (2007).
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Fava C et al. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol. Oncol.(2012).
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Ravandi F et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115(11), 2482–2490 (2009).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119(5), 1123–1129 (2012).
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114(2), 261–263 (2009).
   PubMed Web of Science ®Google Scholar
• Hooi JD, Kester AD, Stoffers HE, Overdijk MM, Van Ree JW, Knottnerus JA. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am. J. Epidemiol. 153(7), 666–672 (2001).
   PubMed Web of Science ®Google Scholar
• Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 110(6), 738–743 (2004).
   Google Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113(11), e463–e654 (2006).
   PubMed Web of Science ®Google Scholar
• Creager MA, Belkin M, Bluth EI et al. 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to develop Clinical Data Standards for peripheral atherosclerotic vascular disease). J. Am. Coll. Cardiol. 59(3), 294–357 (2012).
   PubMed Web of Science ®Google Scholar
• Kim TD, Rea D, Schwarz M et al. Peripheral artery occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia (2013) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Lamina C, Meisinger C, Heid IM et al. Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. Eur.Heart J. 27(21), 2580–2587 (2006).
   PubMed Web of Science ®Google Scholar
• Alzamora MT, Fores R, Baena-Diez JM et al. The peripheral arterial disease study (PERART/ARTPER): prevalence and risk factors in the general population. BMC10, 38 (2010).
   Google Scholar
• Giles FJ, Mauro MJ, Hong F et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 27(6), 1310–1315 (2013).
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP et al. Nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26(10), 2197–2203 (2012).
   PubMed Web of Science ®Google Scholar
• Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur. J. Haematol. 90(6), 531–532(2013).
   PubMed Web of Science ®Google Scholar
• Aichberger KJ, Herndlhofer S, Schernthaner GH et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am. J. Hematol. 86(7), 533–539 (2011).
   PubMed Web of Science ®Google Scholar
• Saglio G, Larson RA, Hughes TP et al. Efficacy and safety of nilotinib in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes in the ENESTnd trial. ASH Annual Meeting Abstracts 116(21), 3430 (2010).
   Google Scholar
• Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J.Clin.Oncol. 22(22), 4653–4655 (2004).
   PubMed Web of Science ®Google Scholar
• Hagerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J. 21(2), 618–628 (2007).
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Turkina A, Shen ZX et al. Expanding Nilotinib Access in Clinical Trials (ENACT): An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer 118(1), 118–126 (2012).
   PubMed Web of Science ®Google Scholar
• Rosti G, Palandri F, Castagnetti F et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 114(24), 4933–4938 (2009).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O'brien S et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J. Clin. Oncol. 28(3), 392–397 (2010).
   PubMed Web of Science ®Google Scholar
• Ventura R, Coccurello R, Andolina D et al. Postnatal aversive experience impairs sensitivity to natural rewards and increases susceptibility to negative events in adult life. Cereb. Cortex (2012).
   PubMed Web of Science ®Google Scholar
• Palandri F, Castagnetti F, Soverini S et al. Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. Haematologica 94(12), 1758–1761 (2009).
   PubMed Web of Science ®Google Scholar
• Pezzilli R, Corinaldesi R, Morselli-Labate AM. Tyrosine kinase inhibitors and acute pancreatitis. JOP 11(3), 291–293 (2010).
   PubMedGoogle Scholar
• Oliva EN, Latagliata R, Lagana C et al. Lenalidomide in international prognostic scoring system low and intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leuk. Lymphoma (2013) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Valent P, Gastl G, Geissler K et al. Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions. Crit. Rev. Oncol. Hematol. 82(3), 370–377 (2012).
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Gugliotta G, Palandri F, Baccarani M. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Crit. Rev. Oncol. Hematol. 82(2), 159–170 (2012).
   PubMed Web of Science ®Google Scholar
• Greenfield S, Billimek J, Pellegrini F et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann. Intern. Med. 151(12), 854–860 (2009).
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40(5), 373–383 (1987).
   PubMedGoogle Scholar
• Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291(20), 2441–2447 (2004).
   PubMed Web of Science ®Google Scholar
• Miller MD, Paradis CF, Houck PR et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 41(3), 237–248 (1992).
   PubMed Web of Science ®Google Scholar